[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 3553 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  2d Session
                                S. 3553

  To review domestic biopharmaceutical manufacturing capabilities in 
 order to improve public health and medical preparedness and response 
capabilities and domestic biopharmaceutical manufacturing capabilities.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                            February 2, 2022

 Mr. Rubio (for himself and Mr. Coons) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
  To review domestic biopharmaceutical manufacturing capabilities in 
 order to improve public health and medical preparedness and response 
capabilities and domestic biopharmaceutical manufacturing capabilities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Agility in Manufacturing 
Preparedness Act''.

SEC. 2. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MANUFACTURING 
              CAPABILITIES.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this section as the ``Secretary''), in cooperation with 
the Director of the Biomedical Advanced Research and Development 
Authority, shall seek to enter into an agreement with the National 
Institute for Innovation in Manufacturing Biopharmaceuticals to perform 
the services described in subsection (b).
    (b) Review and Recommendations.--Under an agreement described in 
subsection (a) between the Secretary, the Director of the Biomedical 
Advanced Research and Development Authority, and the National Institute 
for Innovation in Manufacturing Biopharmaceuticals, the National 
Institute for Innovation in Manufacturing Biopharmaceuticals shall--
            (1) review current domestic biopharmaceutical manufacturing 
        capacity at the Department of Health and Human Services and its 
        adaptability to various threats;
            (2) draft recommendations for developing, demonstrating, 
        deploying, and advancing new domestic biopharmaceutical 
        manufacturing technologies that address gaps identified under 
        paragraph (1) and align Federal technologies with technologies 
        available to the private sector, including through the new 
        BioMAP initiative of the Biomedical Advanced Research and 
        Development Authority; and
            (3) identify other opportunities and priorities to improve 
        the United States public health and medical preparedness and 
        response capabilities and domestic biopharmaceutical 
        manufacturing capabilities.
                                 <all>